Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.29) by 14.58 percent. This is a 2.94 percent increase over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $59.952 million which missed the analyst consensus estimate of $69.792 million by 14.10 percent. This is a 92.73 percent increase over sales of $31.106 million the same period last year.